Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Jun 2007
Randomized Controlled Trial Multicenter StudyLubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Lubiprostone, a locally acting type-2 chloride channel activator, induces intestinal fluid secretion. ⋯ Lubiprostone improved SBM rates in a dose-dependent manner. AEs were tolerable for most patients. Increased AE severity at 72 mcg/day did not provide a clear risk-to-benefit advantage compared with lubiprostone 48 mcg/day, the dose chosen for subsequent Phase 3 studies.